179 related articles for article (PubMed ID: 38500898)
1. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review.
Man RK; Gogikar A; Nanda A; Janga LSN; Sambe HG; Yasir M; Ramphall S
Cureus; 2024 Feb; 16(2):e54268. PubMed ID: 38500898
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.
Chianese M; Screm G; Salton F; Confalonieri P; Trotta L; Barbieri M; Ruggero L; Mari M; Reccardini N; Geri P; Hughes M; Lerda S; Confalonieri M; Mondini L; Ruaro B
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
4. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
5. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
Noor S; Nawaz S; Chaudhuri N
Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data.
Khan MA; Sherbini N; Alyami S; Al-Harbi A; Al-Ghamdi M; Alrajhi S; Rajendram R; Al-Jahdali H
Ann Thorac Med; 2023; 18(1):45-51. PubMed ID: 36968327
[TBL] [Abstract][Full Text] [Related]
8. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
9. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
[TBL] [Abstract][Full Text] [Related]
10. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
11.
Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Ntolios P; Archontogeorgis K; Anevlavis S; Bonelis K; Paxinou N; Voulgaris A; Froudarakis M; Steiropoulos P
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6326-6332. PubMed ID: 34730213
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study.
Cameli P; Refini RM; Bergantini L; d'Alessandro M; Alonzi V; Magnoni C; Rottoli P; Sestini P; Bargagli E
Front Mol Biosci; 2020; 7():581828. PubMed ID: 33102528
[TBL] [Abstract][Full Text] [Related]
15. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
[TBL] [Abstract][Full Text] [Related]
16. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.
Di Martino E; Provenzani A; Vitulo P; Polidori P
Ann Pharmacother; 2021 Jun; 55(6):723-731. PubMed ID: 33054319
[TBL] [Abstract][Full Text] [Related]
18. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
19. Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia.
Sakamoto S; Shimizu H; Isshiki T; Nakamura Y; Kurosaki A; Isobe K; Homma S
Clin Respir J; 2021 Mar; 15(3):272-279. PubMed ID: 33058535
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati F; Stainer A; Polelli V; Mantero M; Gramegna A; Blasi F; Aliberti S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
